NCT04570631CompletedPhase 1
A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 5 Aug 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 1 (actual)
- First submitted
- 25 Jun 2024
- Start date
- 26 May 2021
- Lead sponsor
- AbbVie Deutschland GmbH & Co. KG
- Diseases
- Multiple myeloma
- NCT number
- NCT04570631
- EU CT number
- 2024-512640-36-00
- EudraCT number
- 2020-001983-26
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 1
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l Coordinator of this site? Confirm its status | Meldola | Italy | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.